Dental implants and bisphosphonates
Friends or foes?
The occurrence of osteonecrosis of the jaws has been observed in individuals who take bisphosphonates and have undergone surgical procedures involving the teeth and alveolar bone. The use of bisphosphonates in combination with dental implants is a common treatment approach in the adult population. The aim of this literature review is to analyze and synthesize the scientific evidence from 50 articles related to successful and unsuccessful outcomes of dental implant placement in patients receiving oral or intravenous bisphosphonate therapy. This was achieved by searching, selecting, and analyzing the identified articles to identify patterns, determining factors, and lessons learned from the success and failure cases reported in the scientific literature. A literature search was conducted using the PubMed database, including studies, data, and articles directly related to dental implants and bisphosphonates. Relevant data, such as sample size, main results, and conclusions, were extracted from the articles and analyzed and synthesized using comparative tables to identify trends and differences in the effects of bisphosphonates on implant osseointegration and the observed complications. In conclusion, the comparison of the 50 articles on dental implants and bisphosphonate use reveals that this therapeutic combination can lead to complications, particularly osteonecrosis of the jaws. Approximately 10% of patients treated with dental implants experience complications that can lead to treatment failure.
How to Cite
License
Copyright (c) 2025 Revista Nacional de Odontología
This work is licensed under a Creative Commons Attribution 4.0 International License.
Every single author of the articles has to declare that is an original unpublished work exclusively created by them, that it has not been submitted for simultaneous evaluation by another publication and that there is no impediment of any kind for concession of the rights provided for in the contract.
In this sense, the authors committed to await the result of the evaluation by the journal Revista Nacional de Odontologia before considering its submission to another medium; in case the response by that publication is positive, additionally, the authors committed to respond for any action involving claims, plagiarism or any other kind of claim that could be made by third parties.
At the same time, the authors have to declare that they are completely in agreement with the conditions presented in their work and that they cede all patrimonial rights. These rights involve reproduction, public communication, distribution, dissemination, transformation, making it available and all forms of exploitation of the work using any medium or procedure, during the term of the legal protection of the work and in every country in the world, to the Universidad Cooperativa de Colombia Press.
[1] Marx RE. Pamidronate and zoledronate induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117. DOI: https://doi.org/10.1016/S0278-2391(03)00720-1
[2] Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment. Canada: Quintessence Publishing Co, Inc; 2007;150.
[3] Nightingale SL. From the Food and Drug Administration. JAMA, 1995;274:1578. DOI: https://doi.org/10.1001/jama.1995.03530200014013
[4] Berenson JR, Lichtenstein A, Portel L, Dimopoulos MA, et al. Long-term pamidronate treatment of advanced multiple mieloma patients reduces skeletal events. Myeloma Aredia Study Group. Journal Clin Oncol, 1998;16: 593-602. DOI: https://doi.org/10.1200/JCO.1998.16.2.593
[5] Berenson JR, Lichtenstein A, Portel L, Dimopoulos MA, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple mieloma. N. Engl. J. Med, 1996;334:488-493. DOI: https://doi.org/10.1056/NEJM199602223340802
[6] Berenson JR, Rosen LS, Howell A, Porter L, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001;91:1191-1200. DOI: https://doi.org/10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0
[7] Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res, 2009;20:87-95. DOI: https://doi.org/10.1111/j.1600-0501.2009.01772.x
[8] Memon S, Weltman RL, Katanncik JA. Oral bisphosphonates: Early endosseous dental implant success and crestal bone changes. A restrospective study. International Journal Oral Maxillofacial Implants, 2012;27:1216-1222.
[9] Benford H, Frith J. Auriola S. Mönkkönen J, Rogers M. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological cases of bis phosphonate drugs. Mol Pharmacol, 1999;56:131-140. DOI: https://doi.org/10.1124/mol.56.1.131
[10] Lynch SE, Buser D, Hernandez RA, Weber HP, et al. Effects of the platelet-derived growth factor/insulin-like growth factor-I combination of bone regeneration around titanium dental implants. Results of a pilot study in Beagle dogs. J. Periodontology, 1991;62(9):710-716. DOI: https://doi.org/10.1902/jop.1991.62.11.710
[11] Sykaras N, Triplett RG, Nunn ME, Iocapino AM, et al. Effect of recombinant human bone morphogenic protein-2 of bone regeneration and osseointegration of dental implants. Clin Oral Implants Res, 2001;12:339-349.
[12] Zechner W, Tangl S, Tepper G, Fürst G, et al. Influence of platelet rich plasma on osseous healing of dental implants: A histologic and histomorphometric study in minipigs. Int J Oral Maxillofac Implants, 2003;18:15-22.
[13] Frenkel S, Jaffe W, Della Valle C, Jazrawi L, et al. The effect of alendronate and implant Surface on bone integration and remodeling in a canine model. J Biomed Mater Res, 2001;58:645-650. DOI: https://doi.org/10.1002/jbm.1064
[14] Jakobsen T, Kold S, Bechtold B, Elmengaard B, et al. Local alendronate increases fixation of implants inserted with bone compaction: 12-week canine study. J Orthop Res, 2007;25:432-441. DOI: https://doi.org/10.1002/jor.20276
[15] Jensen T, Bechtold J, Chen X, Soballe K. Systemic alendronate treatment improves fixation of press-fit implants: A canine study using nonloaded implants. J Orthop Res, 2007;25:772-778. DOI: https://doi.org/10.1002/jor.20272
[16] Tengvall P, Skoglund B, Askendal A, Aspenberd P. Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials, 2004;469:514-522. DOI: https://doi.org/10.1016/j.biomaterials.2003.08.049
[17] McKenzie K, Dennis J, Roberts J, Karabasz D, et al. Bisphosphonate remains highly localized after elution from porous implants. Clin Orthop Relat Res, 2011;42:365-371. DOI: https://doi.org/10.1007/s11999-010-1527-x
[18] Wermelin K, Suska F, Tengvall P, Thomsen P, et al. Stainless Steel screws coated with bisphosphonates gave stronger fixation and more surrounding bone. Histomorphometry in rats. Bone, 2008;42:1228-1233. DOI: https://doi.org/10.1016/j.bone.2007.12.065
[19] Meraw SJ, Reeve CM. Qualitative análisis of peripheral peri-implant bone and influence of alendronate sodium on early bone regeneration. J Periodontol, 1999;70:1228-1233. DOI: https://doi.org/10.1902/jop.1999.70.10.1228
[20] Ganguli A, Henderson C, Grant MH, Meikle ST, et al. The interactions of biphosphonates in solution and as coating on hydroxyapatyte. J MaterSci Mater Med, 2002;13:923-931. DOI: https://doi.org/10.1023/A:1019892109411
[21] Goss A, Bartold M, Sambrook P, Hawker P. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: A south australian case series. J Oral Maxillof Surg. 2010;68(2):337-343. DOI: https://doi.org/10.1016/j.joms.2009.09.037
[22] Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws. American association of oral and maxillofacial surgeons position paper on bisphosphonate related osteonecrosis of the jaws. J Oral Maxillof Surg. 2007;65(3):369-376. DOI: https://doi.org/10.1016/j.joms.2006.11.003
[23] Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. Journal of Dental Research. 2007;86(11):1013-1021. DOI: https://doi.org/10.1177/154405910708601101
[24] Cavanna L, Bertè R, Arcari A, Mordenti P, Pagani R, Vallisa D. Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature. European Journal of Internal Medicine. 2007;18(5):417-422. DOI: https://doi.org/10.1016/j.ejim.2006.10.008
[25] Siddiqi A, Payne AG, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: A medical enigma?. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology. 2009;108(3):e1-e8. DOI: https://doi.org/10.1016/j.tripleo.2009.04.027
[26] Ruggiero SL, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice. 2006;2(1):7-14. DOI: https://doi.org/10.1200/jop.2006.2.1.7
[27] Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonateassociated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study. Implant Dentistry. 2010;19(1):29-38. DOI: https://doi.org/10.1097/ID.0b013e3181cec8bc
[28] Don-Wauchope AC, Cole DE. The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clinical Biochemistry. 2009;42(10-11):1194-1196. DOI: https://doi.org/10.1016/j.clinbiochem.2009.02.014
[29] Bedogni A, Bettini G, Totola A, Saia G, Nocini PF. Oral bisphosphonate–associated osteonecrosis of the jaw after implant surgery: A case report and literature review. Journal of Oral and Maxillofacial Surgery. 2010;68(7):1662-1666. DOI: https://doi.org/10.1016/j.joms.2010.02.037
[30] Fleisch H, Russell RG, Bisaz S, Mühlbauer R. Influence of diphosphonates on the deposition and dissolution of calcium phosphate in vitro and in vivo. Helv Physiol Pharmacol Acta.1968;26:CR345–6.
[31] Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165:1264–6. DOI: https://doi.org/10.1126/science.165.3899.1264
[32] Mínguez MP, Llorca CS, Silvestre FJ. Oral implants in patients receiving bisphosphonates: A review and update. Medicina Oral, Patología Oral y Cirugía Bucal. 2008;13(12):E755-E760.
[33] Effect of recombinant human bone morphogenic protein-2 of bone regeneration and osseointegration of dental implants. Clin Oral Implants Res. 2001;12:339–49. DOI: https://doi.org/10.1034/j.1600-0501.2001.012004339.x
[34] Toksvig-Larsen S, Aspenberg P. Bisphosphonate-coated external fixation pins appear similar to hydroxyapatite-coated pins in the tibial metaphysis and to uncoated pins in the shaft. Acta Orthop. 2013;84:314–8. DOI: https://doi.org/10.3109/17453674.2013.797315
[35] Prieto-Alhambra D, Javaid MK, Judge A, Murray D, Carr A, Cooper C. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: Population based retrospective cohort study. BMJ. 2011;343:d7222. DOI: https://doi.org/10.1136/bmj.d7222
[36] Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A register-based national cohort study. J Bone Miner Res. 2009;24:1095–1102. DOI: https://doi.org/10.1359/jbmr.081247
[37] Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010;8:34–39. DOI: https://doi.org/10.1007/s11914-010-0007-2
[38] Abtahi J, Agholme F, Sandberg O, Aspenberg P. Effect of local vs systemic biphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw. J Dent Res. 2013;92:279–83. DOI: https://doi.org/10.1177/0022034512472335
[39] Bobyn JD, Hacking SA, Krygier JJ, Harvey EJ, Little DG, Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J Bone Joint Surg. 2005;87:416–20. DOI: https://doi.org/10.1302/0301-620X.87B3.14665
[40] Von Knoch M, Wedemeyer C, Pingsmann A. The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials. 2005;26:1803–8. DOI: https://doi.org/10.1016/j.biomaterials.2004.06.010
[41] Peter B, Pioletti DP, Laib S. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone. 2005;36:52–60. DOI: https://doi.org/10.1016/j.bone.2004.10.004
[42] Wise LM, Waldman SD, Kasra M. Effect of zoledronate on bone quality in the treatment of aseptic loosening of hip arthroplasty in the dog. Calcif Tissue Int. 2005;77:367–75. DOI: https://doi.org/10.1007/s00223-005-0062-3
[43] Abtahi J, Tengvall P, Aspenberg P. A bisphosphonate-coating improves the fixation of metal implants in human bone. A randomized trial of dental implants. Bone. 2012;50:1148–51. DOI: https://doi.org/10.1016/j.bone.2012.02.001
[44] Koka S, Babu NM, Norell A. Survival of dental implants in post-menopausal biphosphonate users. J Prosthodont Res. 2010;54:208–11. DOI: https://doi.org/10.1016/j.jpor.2010.04.002
[45] Tsetsenekou E, Papadopoulos T, Kalyvas D, Papaioannou N, Tangl S, Watzek G. The influence of alendronate on osseointegration of nanotreated dental implants in New Zealand rabbits. Clin Oral Implants Res. 2012;23:659–66. DOI: https://doi.org/10.1111/j.1600-0501.2011.02189.x
[46] Kasai T, Pogrel MA, Hossaini M. The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc. 2009;37:39–42. DOI: https://doi.org/10.1080/19424396.2009.12222946
[47] Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg. 2010;68:790–6. DOI: https://doi.org/10.1016/j.joms.2009.09.017
[48] Qi M, Hu J, Li J, Li J, Dong W, Feng X. Effect of zoledronate acid treatment on osseointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits. Bone. 2012;50:119–27. DOI: https://doi.org/10.1016/j.bone.2011.10.011
[49] Bell BM, Bell RE. Oral bisphosphonates and dental implants: A retrospective study. J Oral Maxillofac Surg. 2008;66:1022–4. DOI: https://doi.org/10.1016/j.joms.2007.12.040
[50] Stark WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: A case report. Int J Oral Maxillofac Implants. 1995;10:74–8.
